Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Subscribe To Our Newsletter & Stay Updated